Here are the latest quarterly results of NEULAND LABS. For more details, see the NEULAND LABS financial fact sheet and NEULAND LABS share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,687 | 1,715 | 1,727 | 1,810 | 1,862 | 2,036 | 1,919 | 2,054 | |
Other income | Rs m | 6 | 4 | 13 | 5 | 6 | 10 | 18 | 7 | |
Turnover | Rs m | 1,694 | 1,719 | 1,740 | 1,815 | 1,868 | 2,046 | 1,936 | 2,061 | |
Expenses | Rs m | 1,541 | 1,556 | 1,543 | 1,624 | 1,614 | 1,756 | 1,619 | 1,717 | |
Gross profit | Rs m | 146 | 158 | 184 | 186 | 248 | 281 | 300 | 337 | |
Depreciation | Rs m | 59 | 74 | 69 | 76 | 83 | 78 | 76 | 89 | |
Interest | Rs m | 41 | 30 | 47 | 40 | 48 | 57 | 71 | 54 | |
Profit before tax | Rs m | 53 | 59 | 81 | 75 | 123 | 156 | 171 | 202 | |
Tax | Rs m | 9 | 13 | 14 | 19 | 38 | 45 | 264 | 51 | |
Profit after tax | Rs m | 44 | 46 | 67 | 56 | 86 | 110 | -94 | 151 | |
Gross profit margin | % | 8.7 | 9.2 | 10.7 | 10.3 | 13.3 | 13.8 | 15.6 | 16.4 | |
Effective tax rate | % | 16.9 | 22.0 | 16.8 | 25.2 | 30.5 | 29.1 | 154.8 | 25.5 | |
Net profit margin | % | 2.6 | 2.7 | 3.9 | 3.1 | 4.6 | 5.4 | -4.9 | 7.3 | |
Diluted EPS | Rs | 3.4 | 3.6 | 5.2 | 4.4 | 6.7 | 8.6 | -7.3 | 11.7 | |
Diluted EPS (TTM) | Rs | NA | NA | NA | 16.6 | 19.9 | 24.9 | 12.4 | 19.7 | |
![]() |
More Pharmaceuticals Company Quarterly Results: DR. REDDYS LAB CADILA HEALTHCARE WYETH GLENMARK PHARMA BIOCON
Compare NEULAND LABS With: DR. REDDYS LAB CADILA HEALTHCARE WYETH GLENMARK PHARMA BIOCON
Compare NEULAND LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More